Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia

Published on: 

Pharmaceutical Executive

Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.

The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.